GLP-1 receptor agonists, although less potent for triglyceride lowering (20–30%), showed substantial benefit at hepatic and metabolic endpoints, achieving 30–35% reductions in liver fat and histologic resolution of NASH in up to 59% of patients [32]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.